Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study

Phase 2b 12 week dose-finding study found vericiguat, a soluble guanylate cyclase stimulator, was well tolerated, and did not change N-terminal pro-B-type natriuretic peptide and left atrial volume at 12 weeks vs. placebo but was linked to improvements in quality of life.